Sign In
Buy HIMS
$32.16
+1.34 (+4.35%)
At Close: Aug 04, 2026
Hims & Hers partners with Novo Nordisk to sell Wegovy
11:20am, Tuesday, 29'th Apr 2025
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Hims & Hers Stock Rides Wegovy Wave Higher
10:59am, Tuesday, 29'th Apr 2025
Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
10:30am, Tuesday, 29'th Apr 2025
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/mon
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
10:30am, Tuesday, 29'th Apr 2025
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the l
HIMS stock spikes over 40%; Time to buy?
10:27am, Tuesday, 29'th Apr 2025
Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform.⚈ The move positions Hims & Hers to capitalize on booming demand for wei
Hims & Hers pact with Novo de-risks 2025 outlook, says Needham
10:03am, Tuesday, 29'th Apr 2025
Hims & Hers +7.43 (+26.06%) Novo Nordisk +1.96 (+3.13%) 05 May 07 May 12 Jun
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
09:23am, Tuesday, 29'th Apr 2025
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
09:15am, Tuesday, 29'th Apr 2025
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
09:13am, Tuesday, 29'th Apr 2025
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.
08:07am, Tuesday, 29'th Apr 2025
The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
07:52am, Tuesday, 29'th Apr 2025
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many com
Hims & Hers partners with Novo Nordisk to sell Wegovy on its platform
07:44am, Tuesday, 29'th Apr 2025
Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled offering on the telehealth company's platform, the two companies said on Tu
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
07:30am, Tuesday, 29'th Apr 2025
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, mo
Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
05:17pm, Monday, 28'th Apr 2025
Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put option
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
11:05am, Monday, 28'th Apr 2025
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
